Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC

Deborah B Doroshow,Wei Wei,Swati Gupta,Jon Zugazagoitia,Charles Robbins,Blythe Adamson,David L Rimm

Journal of Thoracic Oncology（2021）

引用 14|浏览0

暂无评分

摘要

Among patients with NSCLC treated with first-line pembrolizumab, high PD-L1 TPS is associated with OS among patients with nonsquamous NSCLC, but not among patients with squamous NSCLC.

查看译文

关键词

PD-L1,NSCLC,Histology,Biomarkers

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要